Board of directors

 
 

Anders Ekblom

Anders Ekblom – born 1954, Chairman since 2021 and Board member since 2017 – is a physician, board certified in anaesthesia and intensive care, dentist and Associate Professor in physiology at the Karolinska Institute. Anders Ekblom has extensive experience from the biopharmaceutical industry globally, including being EVP Global Medicines Development at AstraZeneca and CEO and president of AstraZeneca AB Sweden.

Other current positions: Chairman of Elypta AB. Vice chairman LEO Pharma A/S. Board member of AnaMar AB, Mereo BioPharma Group plc and NxtScience AB.

Holdings in Alligator: 37,269 shares

Independent in relation to the Company, its senior management and major shareholders.

Hans-Peter Ostler

Hans-Peter Ostler - born 1971, Vice chairman since 2021 – has University studies in economics and law etc. at the School of Business, Economics and Law and School of Public Administration at Gothenburg University and currently works as wealth manager at Söderberg & Partners. Hans-Peter Ostler has more than 20 years of experience in investment banking and private banking, including from Danske Bank. Hans-Peter Ostler’s previous experiences include assignments such as board member of IRLAD Therapeutics AB.

Other current positions: Board member of Oblique Therapeutics AB, of S.P. HMSO Göteborg AB, of Promore Pharma and InorbitTX.

Holdings in Alligator: 150,000 shares

Independent in relation to the Company, its senior management and major shareholders.

Eva Sjökvist Saers

Eva Sjökvist Saers - born 1962, Board member since 2021 - has a Doctoral degree in pharmaceutical science from Uppsala University. Eva Sjökvist Saers has many years of experience from the pharmaceutical industry where she has worked in various leading positions within Astra/AstraZeneca, Apoteket AB and as CEO of the pharmaceutical company Apotek Produktion & Laboratorier AB (APL) for more than 10 years. Eva Sjökvist Saers is also Chairman of the strategic innovation area Swelife and has previously been Chairman of Apotekarsocieteten and Vice Chairman of SwedenBIO.

Other current positions: Chairman of the board of Dicot AB (publ). Board member of Bluefish Pharmaceuticals AB (publ), IDL Biotech AB (publ) and Oxcia AB. Deputy board member of Brainstorm Aktiebolag.

Holdings in Alligator: None

Independent in relation to the Company, its senior management and major shareholders.

Graham Dixon

Graham Dixon – born 1961, Board member since 2019 - has a PhD in biochemistry from Swansea University and is the CSO/head of R&D at Mithra Pharmaceuticals. Graham Dixon has extensive experience in discovering and developing novel drugs, with applications for both orphan and mainstream disease indications. Previous experiences include inter alia CEO Neem Biotech, head of R&D and CSO of Onxeo, Galapagos, Sensorion Pharma and Addex Therapeutics.

Other current positions: Chairman of HepaRegeniX GmbH.

Holdings in Alligator: None

Independent in relation to the Company, its senior management and major shareholders.

Veronica Wallin

Veronica Wallin - born 1986, Board member since 2021 – has a Master of Science in Business and Economics from Stockholm University. Veronica Wallin is the CFO at the medical technology company Episurf Medical AB since 2017. Veronica Wallin has previously, among other things, been CFO at the pharmacy company ApoEx AB.

Other current positions: Board member for a number of subsidiaries within the Episurf Group.

Holdings in Alligator: 12 500 shares

Independent in relation to the Company, its senior management and major shareholders.

Laura von Schantz

 

Laura von Schantz - born 1982, Board member since 2017 - is a Swedish graduate engineer in biotechnical engineering and has a doctorate in immuno-technology from Lund University. Is the board’s employee representative.

Other current positions: None

Holdings in Alligator: 25 000 employee option stocks in program 2018/2022.